OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density

Abstract

BackgroundWe previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone formation and with decreased bone resorption in postmenopausal women with low BMD.1 Here, we report the results of 2 years of treatment with Romo, followed by 1 year of denosumab (DMAb) or placebo.MethodsThis phase 2 study enrolled 419 postmenopausal women age 55 to 85 years with a lumbar spine, total hip, or femoral neck T-score ≤ –2.0 and ≥ –3.5. For the results described here, women received 1 of 5 regimens of Romo (70 mg QM, 140 mg QM, 210 mg QM, 140 mg Q3M, 210 mg Q3M; data for the 210 mg QM group are shown in the figure) or placebo for 2 years. At the end of 2 years, eligible women entered a 1-year extension phase and were re-randomized 1:1 within their original treatment group to placebo or DMAb 60 mg Q6M. Only women who entered the extension were included in these analyses.ResultsRomo led to rapid and marked increases in lumbar spine and total hip BMD during year 1 and continued increases through year 2. The largest gains were observed with Romo 210 mg QM, with BMD increases of 15.7% (lumbar spine) and 6.0% (total hip) (Figure). Women receiving Romo 210 mg QM who transitioned to DMAb continued to accrue BMD at a rate similar to that in the second year of Romo; in those who transitioned to placebo, BMD returned toward pretreatment levels. Romo induced rapid stimulation of bone formation (P1NP) and decreased bone resorption (CTX). Increases in P1NP were transitory, returning toward baseline within 6 to 12 months and remaining below baseline through year 2. CTX remained below baseline through year 2. In women receiving Romo 210 mg QM who transitioned to DMAb, P1NP and CTX decreased; in those who transitioned to placebo, P1NP gradually returned to pretreatment levels, while CTX initially increased above baseline and gradually returned toward baseline. Adverse events were balanced between the placebo and Romo groups during the first 2 years of the study (with the exception of injection site reactions, most reported as mild) and in the placebo and DMAb groups during year 3.ConclusionsRomo led to rapid and marked increases in lumbar spine and total hip BMD over 2 years, which continued with DMAb and resolved after transition to placebo. These data suggest that the treatment effects observed with Romo are further augmented by follow-on treatments like DMAb.ReferencesMcClung MR, et al. N Engl J Med. 2014;370:412-420Disclosure of InterestM. McClung Grant/research support from: Amgen, Merck, Consultant for: Amgen, Lilly, Merck, A. Chines Shareholder of: Amgen, Employee of: Amgen, J. Brown Grant/research support from: Actavis, Amgen, Eli Lilly, Merck, Novartis, Consultant for: Amgen, Eli Lilly, Speakers bureau: Amgen, Eli Lilly, A. Diez-Perez Shareholder of: Active Life Scientific, Grant/research support from: Amgen, Consultant for: Amgen, Eli Lilly, Speakers bureau: Amgen, Eli Lilly, GSK, Novartis, ViiV, H. Resch: None declared, J. Caminis Sharehol...

PDGFB-based stem cell gene therapy increases bone strength in the mouse

“…One of the potential problems currently in developing anabolic therapies is a resistance to therapy after a year or so of treatment (26). We did not address this issue directly, but we did not see any decrease in ALP levels that were increased after PGK-PDGFB treatment over the 3-mo experimental period.…”

“…Future work is needed to determine if similar results can be achieved in osteoporotic models. In this regard, it is worth noting that anabolic therapy is effective in ovariectomized mice and osteogenic therapy is effective in aged humans (26). Second, we used promoters of different strengths to obtain an appropriate dose of PDGF-BB, which is far too rigid for appropriate dosage control.…”

Sclerostin and skeletal health

“…A recent report described the results of a second year of the phase 2 trial and a 1 year extension in which participating subjects were re-randomized 1:1 within their original treatment group to receive either placebo or denosumab 60 mg every 6 months [50]. The rapid and marked increases in lumbar spine and total hip BMD observed during year 1 continued increase through year 2.…”

Romosozumab/CDP7851 for the treatment of osteoporosis

“…The results of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo have recently been reported in abstract form [68]. The initial 12-month treatment phase was extended to 24 months, followed by a 12-month extension phase whereby participants are randomized 1:1 to receive either denosumab or placebo every 6 months.…”